Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes

Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes

Item

http://www.wikidata.org/entity/Q34164594

Q34164594

about

Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections Healthcare-associated infections, infection control and the potential of new antibiotics in development in the USA Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections Targeting Antibiotic Resistance Clinical management of infections caused by multidrug-resistant Enterobacteriaceae Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.Antibiotics and bacterial resistance in the 21st century.Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens.Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.Ceftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections.Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.Current epidemiology and growing resistance of gram-negative pathogens.Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection Pipeline of Known Chemical Classes of Antibiotics.Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosa In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates New β-lactam-β-lactamase inhibitor combinations in clinical development.Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on.β-Lactamase inhibitors: a review of the patent literature (2010 - 2013).New antibiotics for bad bugs: where are we?Cephalosporins currently in early clinical trials for the treatment of bacterial infections.Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.Multidrug-resistant Gram-negative bacteria in solid organ transplant recipients with bacteremias.Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.Development of novel antibacterial drugs to combat multiple resistant organisms.Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia.Emerging drugs for nosocomial pneumonia.Recent Advances in the Rational Design and Optimization of Antibacterial Agents.Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.

P2860

Q26747429-666099A7-7979-4F10-8FD2-113D41BA58F6 Q26995305-49CB8BA5-4050-4F8D-9C4B-D317535508D9 Q27001490-ADE0120A-AB9E-4AD7-B623-CFD7B8490A9B Q28069563-937BDBC9-5E74-47E7-859B-5919CB18DE57 Q28078130-76BA32D0-30D5-4F26-B0FD-305A2920107D Q28246841-64930108-1031-4008-BE57-0CF63EF4BE19 Q33623078-35EB0D84-7B98-402C-9720-7894DFF84BEE Q34057425-116E3E37-7FD6-4866-B4A1-DC6BDDB94792 Q34156349-2BB184CA-65B4-4342-BFE6-5929FE398360 Q34298994-18FC0AD4-042B-4FCD-8BCA-D2579F9004B0 Q34299064-ED0FFC33-5096-4636-8132-3C9DD9B23E61 Q34320027-7AAB06D4-4C53-4867-922B-06D331AD1466 Q34334699-EA598821-674C-4715-92DB-FE38732215DD Q34393008-156F43EE-2603-42B5-BC39-5B7F88800462 Q34688710-7795B377-22AB-4376-9465-7F749B31DB07 Q35004269-BEADFBC7-114D-456A-8FB0-70CC6C7595AF Q36018548-11DB679C-F3C3-4A52-BBFA-02C74A471A26 Q36025192-5B26F0BE-F2F9-4AAC-823D-CE7E573C079A Q36172484-75239600-C714-436D-966E-D23D8000EB96 Q36438924-EDF33674-BC3B-462A-A336-ABF16D192BC8 Q36683409-0199D139-B0F4-450B-A4B5-AF121DEF0BED Q37123987-719849C5-1124-4E0F-ACDF-4AF89E7D49CF Q37263317-7E313276-09B6-44D1-9C2E-8AFA211E7267 Q37335781-C42660AB-F049-49F2-A86D-615049BE6036 Q37544754-55860B0B-F664-432D-B3D2-69CDAAA4DB4A Q38076455-C4337026-FD23-4572-B289-3DDA95D5644B Q38115356-2E08E0B0-507E-4213-902B-DD8AA3F674CB Q38130715-11FC8C2C-30DF-4F96-8F53-3E8F7DAC42F4 Q38132217-5B9C71A4-D35B-48AF-9CF9-35616A962BFA Q38222497-A0C22B5A-FE3A-4942-8A28-AC36B58A77C0 Q38241417-B6AA10F9-BB9E-4096-A57D-73261961CA74 Q38267323-AFDE7237-844E-4999-ABBB-B3A99B911524 Q38296151-3BA7B95A-2473-4D15-BA14-56F2C1489240 Q38350301-6EF0A961-5FBD-438B-A0E9-8D3D2055C47B Q38541624-260C024A-AE88-4102-B472-B4841D5B4E94 Q38650049-42B34010-9A23-4124-8EF6-CB90F26D0327 Q38783043-61CB5715-4604-49DD-A49E-A5B21A6BDEFC Q38878167-3CDE7ABE-6025-471B-9CF6-169077CFD8DA Q38958278-97699655-CC4C-4F7B-B500-577079A4FDFB Q38981397-89E4EF59-7E71-4C83-BC19-827B78D0FAE1

P2860

Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes

Item

http://www.wikidata.org/entity/Q34164594

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu